P15 Anti-carbamylated protein antibodies’ levels are negatively correlated with circulating effector T-cells in a cohort of patients with systemic lupus erythematosus

Background/Purpose Anti-carbamylated protein antibodies (anti-CarP) were detected in a large cohort of patients with Systemic Lupus Erythematosus (SLE) in correlation with erosive arthritis but not with disease activity indexes. In animal models, T-cells may be activated by carbamylated epitopes playing a role in the development of arthritis. The imbalance between circulating regulatory (Treg) and CD28- effector T-cells was described in active SLE patients, explaining its involvement in disease’s pathogenesis. Actually, no data are available about the possible correlation with these T-cell subpopulations and anti-CarP levels in SLE. Methods Eight SLE patients with a median (10th-90th percentile) SLEDAI-2K=0 (0–4), anti-dsDNA levels=34.1 (15.6–427.4) UI/ml (nv Results Enrolled patients showed levels of anti-CarP=189.38 (93.5–341.1) AU/ml, Treg=2.2 (% of CD4+), CD4+CD28-=7.7 (4.8–22.5) (% of CD4+) and CD8+CD28-=30.3 (17.2–35.6) (% of CD8+). Analyzing possible correlations among different T-cell subtypes and anti-CarP levels, a significant inverse correlation was found between these autoantibodies and CD4+CD28- T cells (r=-0.8, p Conclusions In a small cohort of patients with serologically active SLE, anti-CarP autoantibodies were found as negatively correlated to circulating CD4+CD28- T-cells, which were described in association with disease damage, independently of age, gender, disease duration and activity. This suggest a potential role of anti-CarP as marker of SLE with a minor extent of T-cell activation and, consequently, with a possible better prognosis.